Risk factor
Very poor trading liquidity
Profitability factor
Overvalued vs peers
About
Taiwan Biomaterial Co., Ltd. engages in the development and sale of medical devices in Taiwan. The company provides Foamagen, a foamy dura substitute; stroke thrombus negative pressure removal catheter system comprising suction and removal of cerebrovascular embolism blood clot for the pump system, and the nickel-titanium guidewire for guiding cerebral vascular surgery; and tissue repair and regeneration products for the treatment of early osteoarthritis. Taiwan Biomaterial Co., Ltd. Was founded in 2010 and is based in Zhubei, Taiwan.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITDA, o
Buy
Sell